Multiple Myeloma Market Size, Share, Growth Analysis, By Drug Class(Proteasome Inhibitors, Immunomodulatory Drugs, Monoclonal Antibodies, and Steroids), By Therapy(Immunotherapy, Chemotherapy, Radiation Therapy, and Stem Cell Transplant), By Distribution channel(Hospital, Retail, and Online Pharmacies), By Region - Industry Forecast 2024-2031

North America is estimated to secure the top spot when it comes to the multiple myeloma market. Surging incidence of multiple myeloma, high investments in oncology R&D, and growing geriatric population are some key factors that are estimated to aid the dominance of North America in the future. The United States is projected to spearhead the demand for multiple myeloma treatment followed by Canada going forward. High patient awareness regarding symptoms of multiple myeloma, availability of novel treatment therapies and drugs, and shorter approval times for novel therapies are also estimated to aid the dominance of North America in the long run.

Growing awareness regarding symptoms of multiple myeloma is helping Asia Pacific emerge as the fastest-growing market for multiple myeloma companies in the world. High investments in healthcare infrastructure development, launch of new awareness initiatives, and increasing healthcare expenditure are some major factors helping generate new opportunities for market players. As per this multiple myeloma market forecast, China, Japan, and India are expected to be highly opportune markets for multiple myeloma companies owing to a major surge in senescent population in these countries. Increasing availability of novel multiple myeloma treatment therapies and drugs coupled with high emphasis on early diagnosis are also estimated to benefit the multiple myeloma industry in this region.